IndraLab
Statements
"We conclude that PrP traps CYLD, preventing it from binding and deubiquitinating RIP1 and TRAF2."
reach
"TNFR1 activation together with the absence of c-IAPs (IAP antagonist treatment), translation inhibition (cyclohexamide treatment), or RIP1 deubiquitination by the deubiquitinating enzyme (DUB) CYLD may promote the translocation of RIP1 to a secondary cytoplasmatic complex, Complex II [XREF_BIBR - XREF_BIBR]."
reach
"When RIPK1 is not ubiquitinated, complex IIb is formed; in order for this to occur, the cylindromatosis tumour suppressor protein DUB (CYLD) enzyme deubiquitinates RIPK1, thereby allowing it to disassociate from complex I 42 and form complex IIb, whereby TRADD is replaced by RIPK3, upon degradation of cIAP1 and 2 XREF_BIBR, XREF_BIBR, XREF_BIBR."
reach
"TNFR1 activation with no integration of c-IAPs (e.g. with the treatment of IAP antagonists), or with inhibition of translation, or with deubiquitination of RIPK1 by the deubiquitinating enzyme CYLD may induce RIPK1 translocation to a secondary complex in the cytoplasm called complex II [XREF_BIBR - XREF_BIBR]."
reach
"As the deubiquitination of RIP1 by CYLD, a major deubiquitinase in the NF-kappaB pathway that functions by hydrolysing K63 and linear ubiquitin chains XREF_BIBR, is a key step to induce complex II formation XREF_BIBR and OPTN associates with CYLD XREF_BIBR, defects in CYLD deubiquitination activity, due to the absence of OPTN, may result in enhanced complex II formation."
reach
"The cIAPs can ubiquitinate RIP1, which leads to activation of NF-κB and MAPK pathways to promote cell survival.39 40 Upon cIAP degradation, RIP1 can be de-ubiquitinated by deubiquitinase cylindromatosis (CYLD).41 Upon deubiquitination, Complex IIa forms (Fig. 3), which typically includes RIP1, caspase-8, and FADD.38 42 Formation of this complex can trigger cell death by apoptosis."